The approved GLP-1 agonist and the investigational triple agonist

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and for weight management, with a completed phase 3 programme; STEP 1, published by Wilding and colleagues in NEJM in 2021, reported a mean weight reduction of 14.9 per cent against 2.4 per cent for placebo over 68 weeks in 1,961 adults. Retatrutide has phase 2 data only, and no trial has compared the two.

What semaglutide established

A single-receptor agonist with a large phase 3 programme in both diabetes and obesity, cardiovascular outcome data, and years of post-approval use. STEP 1 is the reference obesity trial for the class, and its 68-week design and 1,961 participants set the scale against which later trials are read.

It engages one of the three receptors retatrutide engages.

Where retatrutide differs

Two additional receptors, an engineered potency balance across all three, and a smaller, shorter, earlier-phase evidence base. The mechanistic rationale for the additions is set out in the discovery paper; whether it produces a different clinical result against semaglutide is untested.

The phase 2 obesity figure of 24.2 per cent at 48 weeks and the STEP 1 figure of 14.9 per cent at 68 weeks come from trials that share no participants and differ in nearly every design parameter.

What is published and what is not

No trial has randomised participants between retatrutide and semaglutide. Statements that retatrutide outperforms semaglutide are inferences from separate trials, and the papers themselves make no such claim.

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What semaglutide established?

A single-receptor agonist with a large phase 3 programme in both diabetes and obesity, cardiovascular outcome data, and years of post-approval use. STEP 1 is the reference obesity trial for the class, and its 68-week design and 1,961 participants set the scale against which later trials are read.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.